SEMG-1 expression in early stage chronic lymphocytic leukemia.
Cytotherapy (2009), Volume 11, Page 238
Abstract:
Chronic lymphocytic leukemia (CLL) is an indolent disease. It is currently recommended that patients with CLL stages 0 and I follow a watchful waiting strategy. These patients are, therefore, a suitable group for testing immunotherapeutic approaches to avoid problems of immunosuppression as a result of disease progression and chemotherapy. In this study, we investigated the expression of SEMG-1 in early CLL to determine the suitability of SEMG-1 as a target for further development of tumor vaccines for early CLL.
Polymerases:
Topics:
Status:
new | topics/pols set | partial results | complete | validated |
Results:
No results available for this paper.